According to the findings of an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) says that no added benefit was proven for UK pharma major GlaxoSmithKline's (LSE: GSK) Anoro Ellipta (vilanterol/umeclidinium).
For patients with moderate chronic obstructive pulmonary disease (COPD) severity and patients with fewer than two acute flare-ups (exacerbations) per year, evaluable data were only available on the outcomes “dyspnoea” and “health-related quality of life.” However, these data showed no differences in comparison with tiotropium. For higher severity grades with more exacerbations, the drug manufacturer presented no evaluable analyses at all, said the IQWiG.
Data only for patients with few exacerbations
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze